290 related articles for article (PubMed ID: 31759938)
1. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
Baum SJ; Sampietro T; Datta D; Moriarty PM; Knusel B; Schneider J; Somaratne R; Kurtz C; Hohenstein B
J Clin Lipidol; 2019; 13(6):901-909.e3. PubMed ID: 31759938
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
[TBL] [Abstract][Full Text] [Related]
3. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
Lappegård KT; Enebakk T; Thunhaug H; Hovland A
Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
5. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
6. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01).
Torres E; Goicoechea M; Hernández A; Rodríguez Ferrero ML; García A; Macías N; Anaya F
J Clin Apher; 2020 Jan; 35(1):9-17. PubMed ID: 31663632
[TBL] [Abstract][Full Text] [Related]
8. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
9. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
10. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
[TBL] [Abstract][Full Text] [Related]
11. Evolocumab in patients with homozygous familial hypercholesterolemia in India.
Bansal S; Ruzza A; Sawhney J; Kulkarni G; Iyengar S; Mehta V; Hamer A; Wu Y; Raal FJ
J Clin Lipidol; 2021; 15(6):814-821. PubMed ID: 34750081
[TBL] [Abstract][Full Text] [Related]
12. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
13. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
14. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
[TBL] [Abstract][Full Text] [Related]
15. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
[TBL] [Abstract][Full Text] [Related]
16. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
17. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Blom DJ; Djedjos CS; Monsalvo ML; Bridges I; Wasserman SM; Scott R; Roth E
Circ Res; 2015 Sep; 117(8):731-41. PubMed ID: 26228031
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
[TBL] [Abstract][Full Text] [Related]
19. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC; Windecker S; Pedrazzini G; Mueller C; Cook S; Matter CM; Muller O; Häner J; Gencer B; Crljenica C; Amini P; Deckarm O; Iglesias JF; Räber L; Heg D; Mach F
J Am Coll Cardiol; 2019 Nov; 74(20):2452-2462. PubMed ID: 31479722
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
Santos RD; Stein EA; Hovingh GK; Blom DJ; Soran H; Watts GF; López JAG; Bray S; Kurtz CE; Hamer AW; Raal FJ
J Am Coll Cardiol; 2020 Feb; 75(6):565-574. PubMed ID: 32057369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]